Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-06-10
2009-12-15
Berch, Mark L (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C540S302000, C548S204000, C546S334000
Reexamination Certificate
active
07632828
ABSTRACT:
The present invention provides β-methyl carbapenem compounds and pharmaceutical compositions useful in the treatment of bacterial infections and methods for treating such infections using such compounds and/or compositions, wherein the compounds are generally of the FormulaeThe invention includes administering an effective amount of a carbapenem compound or salt and/or prodrug thereof to a host in need of such a treatment. The present invention is also in the field of synthetic organic chemistry and is specifically provides an improved method of synthesis of ÿ-methyl carbapenems which are useful as antibacterial agents.
REFERENCES:
patent: 3950357 (1976-04-01), Kahan et al.
patent: 4866171 (1989-09-01), Kumagai et al.
patent: 4933333 (1990-06-01), Sunagawa et al.
patent: 4943569 (1990-07-01), Sunagawa
patent: 4962103 (1990-10-01), Sunagawa et al.
patent: 5011832 (1991-04-01), DiNinno et al.
patent: 5034384 (1991-07-01), Greenlee et al.
patent: 5068232 (1991-11-01), Ziegler et al.
patent: 5122604 (1992-06-01), Sunagawa et al.
patent: 5607928 (1997-03-01), Arnould
patent: 6255300 (2001-07-01), DiNinno et al.
patent: 6277843 (2001-08-01), Dininno et al.
patent: 6310055 (2001-10-01), DiNinno et al.
patent: 6399597 (2002-06-01), Cama et al.
patent: 2006/0069081 (2006-03-01), Choi et al.
patent: 0 292 191 (1988-11-01), None
patent: 2092147 (1982-08-01), None
patent: 59036677 (1984-02-01), None
patent: WO 99/12928 (1999-03-01), None
Arnould et al., Bioorganic & Medicinal Chemistry Letters vol. 6, Issue 20 , Oct. 22, 1996, pp. 2449-2454.
Bersier et al., Electroanalysis vol. 2, Issue 5, pp. 373-381 (1990).
Aldridge, K. E., “Ertapenem (MK-0826), a new carbapenem: comparative in vitro activity against clinically significant anaerobes”Diagn. Microbiol. Infect. Dis., 44(2):181-6 (Oct. 2002).
Ambler, R.P., et al., “A standard numbering scheme for the class A beta-lactamases,”Biochem. J., 276 (pt. 1):269-270 (May 15, 1991).
Arnould, J.C., et al., “Synthesis and antibacterial activity of lipophilic carbapenems with anti-MRSA activity,”Bioorg. Med. Chem. Lett., 6(20):2449-2454 (Oct. 22, 1996).
Bouffard, F.A., et al., “Thienamycin total synthesis. 1. Synthesis of azetidinone precursors of (±)-thienamycin and its stereoisomers,”J. Org. Chem., 45(6), 1130-1142 (1980).
Cunha, B.A., “Ertapenem. A review of its microbiologic, pharmacokinetic and clinical aspects,”Drugs Today(Barc.), 38(3):195-213 (Mar. 2002).
Edwards, J.R., et al., “In vitro antibacterial activity of SM-7338, a carbapenem antibiotic with sta-bility to dehydropeptidase I,”Antimicrob. Agents Chemother., 33(2):215-222 (Feb. 1989).
Hazumi, N., “Mechanism of enhanced antipseudomonal activity of BO-2727, a new injectable 1-beta-methyl carbapenem,” et al.,Antimicrob. Agents Chemother., 39(3):702-706 (Mar. 1995).
Inoue, K., et al., “In vitro antibacterial activity and beta-lactamase stability of a new carbapenem, BO-2727,”Antimicrob. Agents Chemother., 39(10):2331-2336 (Oct. 1995).
Johnston, D.B.R., et al., “Total synthesis of (±)-thienamycin,”J. Am. Chem. Soc., 100(1):313-315 (1978).
Kahan, J.S., et al., “Thienamycin, a new beta-lactam antibiotic. I. Discovery, taxonomy, isolation and physical properties,”J. Antibiot.(Tokyo), 32(1):1-12 (Jan. 1979).
Leanza, W.J., et al., “N-Acetimidoyl- and N-formimidoylthienamycin derivatives: antipseudomonal beta-lactam antibiotics,”J. Med. Chem., 22(12):1435-1436 (Dec. 1979).
Lin, W., et al., “Reduction of azides to amines or amides with zinc and ammonium chloride as reducing agent,”Synthetic Communications, 32:3279-3284 (2002).
Nakagawa, S., et al., “In vitro activity of a new carbapenem antibiotic, BO-2727, with potent antipseudomonal activity,”Antimicrob. Agents Chemother., 37(12):2756-2759 (Dec. 1993).
Neu, H.C., et al., “In vitro activity and beta-lactamase stability of a new carbapenem, SM-7338,”Antimicrob. Agents Chemother., 33(7):1009-1018 (Jul. 1989).
Odenholt, I., et al., “Comparative in vitro pharmacodynamics of BO-2727, meropenem and imipenem against Gram-positive and Gram-negative bacteria,”Clin. Microbiol. Infect., 3(1):73-81 (Feb. 1997).
Salzmann, T.N., et al., “A stereocontrolled synthesis of (+)-thienamycin,”J. Am. Chem. Soc. 102(19):6161-6163 (1980).
Shah, P.M., and Isaacs, R.D., “Ertapenem, the first of a new group of carbapenems,”J. Antimicrob. Chemother., 52(4):538-542 (Oct. 2003) (published electronically Sep. 1, 2003).
Shimada, J., and Kawahara, Y., “Overview of a new carbapenem, panipenem/betamipron,”Drugs Exp Clin Res., 20(6):241-245 (1994).
Weaver, S.S., et al., “Thienamycin: new beta-lactam antibiotic with potent broad-spectrum activity,”Antimicrob. Agents Chemother., 15:518-521 (1979).
Arnould, J. et al., “New Applications of the Mitsunobu Reaction in the Synthesis of C-2 N-Methyl Carbapenems,”Tetrahedron Letters, 1992, vol. 33, No. 47, pp. 7133-7136.
Chung, J. et al., “Sequential Nitromethane Conjugate Addition/Elimination-Pd-Catalyzed Allylation of β-Trifloxy Acrylates. Application to Carbapenem Synthesis,”Organic Letters, 1999, vol. 1, No. 11, pp. 1783-1785.
Imuta, M. et al., “Carbapenem and Penem Antibiotics. VI. Synthesis and Antibacterial Activity of 2-Heteroaromatic-Thiomethyl and 2-Carbamoyloxymethyl 1-Methylcarbapenems,”Chemical and Pharmaceutical Bulletin, 1991, vol. 39, No. 3, pp. 663-671.
Uyeo, S. et al., “Practical, Stereocontrolled Synthesis of 2-Functionalized-methyl-1β-methylcarbapenems,”Tetrahedron Letter, 1994, vol. 35, No. 25, pp. 4377-4378.
Wilkening, R. et al., “Synthesis and Activity of 2-(Sulfonamido)methylcarbapenems: Discovery of a Novel, Anti-MRSA 1,8-Naphthosultam Pharmacophore,”Bioorganic&Medicinal Chemistry Letters, 1999, vol. 9, No. 5, pp. 673-678.
Ziegler, C. et al., “An Intramolecular Addition-Elimination Strategy for the Synthesis of Carbapenems,”Tetrahedron, 1994, vol. 50, No. 42, pp. 12085-12096.
Bouygues Martin
Choi Woo-Baeg
Hager Michael W.
Kim Deog-Il
Menaldino David S.
Berch Mark L
FOB Synthesis, Inc.
King & Spalding
LandOfFree
Gram-positive carbapenem antibacterials and processes for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Gram-positive carbapenem antibacterials and processes for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Gram-positive carbapenem antibacterials and processes for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4086205